Decreased Expression of 15-hydroxyprostaglandin Dehydrogenase in Gastric Carcinomas.
10.3349/ymj.2008.49.6.917
- Author:
Tae Jung JANG
1
;
Ye Seob JI
;
Ki Hoon JUNG
Author Information
1. Department of Pathology, Dongguk University College of Medicine, Kyongju, Korea. taejung@mail.dongguk.ac.kr
- Publication Type:Original Article
- Keywords:
15-hydroxyprostaglandin dehydrogenase;
gastric carcinoma;
methylation
- MeSH:
Aged;
Base Sequence;
DNA Methylation;
DNA Primers/genetics;
DNA, Neoplasm/genetics;
Female;
Humans;
Hydroxyprostaglandin Dehydrogenases/genetics/*metabolism;
Male;
Middle Aged;
Promoter Regions, Genetic;
Stomach Neoplasms/*enzymology/genetics
- From:Yonsei Medical Journal
2008;49(6):917-922
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Gastric carcinoma tissues release high level of prostaglandin E2 (PGE2) when compared to non-neoplastic mucosa, and cyclooxygenase-2 (COX-2), which is the rate-limiting enzyme in prostaglandin (PG) biosynthesis, is often overexpressed in gastric carcinomas and during gastric carcinogenesis. However, little is known about the expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the key enzyme responsible for the biological inactivation of PG, in gastric carcinomas. MATERIALS AND METHODS: We investigated the expression of 15-PGDH in 28 cases of advanced gastric carcinomas by Western blot analysis and also the relation between its expression and the gene promoter methylation. RESULTS: 15-PGDH expression was significantly decreased in gastric carcinomas compared to corresponding non-neoplastic tissues and inversely correlated with the expression of proliferating cell nuclear antigen in gastric carcinomas. However, there was no correlation between 15-PGDH expression and pathological findings such as nodal metastasis and vascular invasion. Promoter hypermethylation of 15-PGDH gene was not detected in carcinomas, with only a negligible expression of the enzyme. CONCLUSION: Our results suggested that 15-PGDH has tumor suppressor activity in gastric carcinomas.
